Glycotope: Pentixapharm acquires target discovery business of Berlinbased Glycotope
Pentixapharm AG, a clinical─stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July
Read full article »
Glycotope engages in drug development, analytics, glycobiology and cell biology to develop pharmaceutical therapeutics and nutrition additives.
Read more